Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Steven Pipe, MD, Michael Becka, Elke Detering, Konstantina Vanevski, Toshko Lissitchkov

Blood (2019) 134 (Supplement_1): 4630.

https://doi.org/10.1182/blood-2019-125764

Published: 2019

Journal Articles

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

Dagmar Kubitza, MD, Michael Becka, PhD, Wolfgang Mueck, PhD, Michael Zuehlsdorf, PhD

Blood (2006) 108 (11): 905.

https://doi.org/10.1182/blood.V108.11.905.905

Published: 2006

Journal Articles

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Atef Halabi, MD, Haidar Maatouk, MD, Norbert Klause, MD, Volkmar Lufft, MD, Dagmar Kubitza, MD, Michael Zuehlsdorf, PhD, Michael Becka, PhD, Wolfgang Mueck, PhD, Rafael Schäfers, MD, Dominic Wand, Thomas Philipp, MD, Heike Bruck, MD

Blood (2006) 108 (11): 913.

https://doi.org/10.1182/blood.V108.11.913.913

Published: 2006

Journal Articles

Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.

Dagmar Kubitza, MD, Michael Becka, MD, Michael Zuehlsdorf, MD, Wolfgang Mueck, MD

Blood (2005) 106 (11): 1872.

https://doi.org/10.1182/blood.V106.11.1872.1872

Published: 2005

Journal Articles

Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Dagmar Kubitza, MD, PhD, Michael Becka, MD, Wolfgang Mueck, MD, Michael Zuehlsdorf, MD

Blood (2005) 106 (11): 1873.

https://doi.org/10.1182/blood.V106.11.1873.1873

Published: 2005

NARROW

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.

Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.

Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only